[Clinical impact of atypical antipsychotics: prospective 6-month study of inpatients treated with risperidone or olanzapine]. / Impact clinique des neuroleptiques atypiques: étude prospective sur 6 mois en milieu hospitalier de patients traités par rispéridone ou olanzapine.

ABSTRACT

A survey of clinical and therapeutic evolution in patients treated with an atypical antipsychotic, risperidone or olanzapine, was carried out at La Colombière Psychiatric Hospital, Montpellier. This prospective observational study was conducted over 6 months. Forty-nine patients were included in the olanzapine treatment group and thirty-five in the risperidone treatment group. The Clinical Global Impression (CGI) scale was used for evaluation at day 0, 7, 30, 90 and 180 of treatment. The majority of patients were improved after 30 days of treatment, and clinical improvement was observed in about 60 per cent of patients among those treated at day 180. The main therapeutic benefit occurred in respect of positive psychotic symptoms. Patients were discharged after 30 days of treatment. The atypical antipsychotic was not used with an additional neuroleptic for all patients. Tolerance was good, particularly for olanzapine. On the other hand, according to our results, others studies have to be performed to confirm the impact of the treatment on weight gain, assessment of subjective elements such as sedation, and the direct effect of the atypical antipsychotics on primary negative symptoms.